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ABSTRACT
Objectives: This study will investigate the phenotype of Glucose transporter 1 (GLUT1) in endometrial cancer and the 
association of its expression with tumor’s clinicopathological factors. 
Material and methods: Standard immunohistochemistry (IHC) staining protocol was utilized to identify the location and 
expression pattern of GLUT1 in a panel of 71 endometrial carcinomas compared to 30 normal tissues using tissue microarrays. 
Results: High scores of GLUT1 staining are more frequent in cancer cases, it was recognized in 64 (90%) endometrial 
cancers and 12 (40%) control cases. Tissue histotype (cancer versus non-cancerous) was associated with IHC staining of 
GLUT1 (p = 0.000). Significant association between strong GLUT1 staining of malignant epithelial cells and stage of tumor 
(p = 0.000) was observed, advanced disease stages were more prevalent with high GLUT1 staining in malignant epithelial 
cells. There is also a significant association between high scores of GLUT1 staining and location of expression in transformed 
epithelium, cytoplasmic and membranous (p = 0.000), 100% of cases with cytoplasmic and membranous expression showed 
high GLUT1 staining scores. Considerable varied survival models were observed with positive GLUT1 neoplasm regard-
ing diagnosis, grade, stage, differentiation, and recurrence (p-values 0.000, 0.000, 0.000, 0.002, and 0.000 respectively). 
Survival estimates are considerably healthier in positive GLUT1 staining cases of endometrial carcinoma, which have low 
grade, low stage and no recurrence. 
Conclusions: GLUT1 expression has been found upregulated in endometrial carcinoma. IHC staining of GLUT1 can be 
a supportive mean in predicting prognosis and survival estimates of endometrial carcinoma with specific clinical factors.
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INTRODUCTION
Endometrial cancer (EC) is the second most frequent 
malignant neoplasm of the female reproductive system 
in USA [1]. In Saudi Arabia, uterine corpus tumors are 
the most frequent cancer of female genital system [2]. 
More than 400 cases of endometrial cancer were registered 
in 2015, which represented about 6.4 % of all recently 
confirmed cancer cases of all sites [2]. The mean age was 
61 years (22–99). The most common morphological type 
is endometrioid adenocarcinoma not otherwise specified 
(NOS) accounts for 63.8 percent, and less commonly ad-
enocarcinoma (NOS) 11.9%, carcinoma (NOS) 3.2%, serous 
cystadenocarcinoma 3.2%, papillary serous cystadenocar-
cinoma 3.0% and others [2]. Diagnosis and management 
of endometrial neoplasms depend greatly on patients’ 
clinicopathological factors [patient age, tumor size and 
histological type as well as Fédération Internationale 
de Gynécologie Obstétrique (FIGO) grade as prognos-
tic signs]. Yet, these clinical factors are not adequate to 
predict disease’s outcomes due to endometrial tumors 
heterogeneity [3]. Regardless of significant improvements 
in cancer management and the good prognosis of en-
dometrial tumors, about 15% of all endometrial tumors 
recur, of which up to 90% of recurrent tumors happen 
within 3 years [4]. The recurrent disease prognosis is poor; 
the median survival barely surpasses twelve months. At 
present, the total number of patients with recurrent en-
dometrial tumor arises [5].
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So, it is a pleading demand to find better diagnostic 
and prognostic markers and chemotherapeutic agents to 
facilitate clinical tasks for effective diagnosis, prognosis 
and treatment of endometrial carcinoma. Concentrated 
experimental works have been constructed to acquire new 
markers so as to support disease diagnosis and prognosis, 
improve patients’ risk stratification and advance clinical 
management [6]. The majority of these biomarkers has not 
been satisfactorily specific or sensitive; this lead to a big 
interest in distinguishing biomarkers of transformed cells 
and tumor micro-environment which could have prognostic 
or predictive values of response to particular medications 
that could lead to proper therapy.
Glucose transporter 1 (GLUT1) is upregulated in a wide 
spectrum of human malignancies and its expression is ab-
sent in most types of normal epithelial cells. The expres-
sion of GLUT1 appears to be a potential marker for ma-
lignant transformation [7–8]. GLUT1 has been considered 
to have a significant role in the development of different 
neoplasms once overexpressed. Many recent studies as-
sociated GLUT1 expression with increased malignant po-
tential, invasiveness, diagnosis, prognosis and survival in 
different neoplasms, including prostate, breast, colorectal, 
ovarian, lung, hepatic, pancreatic, esophageal and cervical 
carcinomas [8–10]. However, in endometrial cancer, many 
studies attempted to find similar association and prove 
that GLUT1 phenotype could be utilized as a diagnostic 
and prognostic tissue marker, but the findings were incon-
sistent and need further confirmation [11–22]. Therefore, 
this manuscript will describe the immunohistochemistry 
phenotype of GLUT1 in a panel of endometrial carcinomas 
compared to normal tissues, and analyse its relationship with 
clinicopathological features, to determine its clinical value 
and its role in endometrial cancer. Furthermore, this study 
will evaluate a GLUT1 expression as a diagnostic marker and 
predictor of survival in patients with endometrial carcinoma.
Objectives
This study will investigate the phenotype of Glucose 
transporter 1 (GLUT1) in endometrial cancer and the associa-
tion of its expression with tumor’s clinicopathological factors.
 MATERIAL AND METHODS
Two groups of tissue samples were included in this 
study; the first group is 71 specimens related to patients 
with histologically confirmed endometrial carcinomas. The 
second group is 30 tissue samples from curetted patients 
for noncancerous conditions (4 endometrial polyps, 16 pro-
liferative endometrium, and 10 secretory endometrium), as 
a control. The mean age of second group individuals was 
36 (ranged 22–50). All ethical rules and regulations adapted 
by author institution have been followed.
This study will utilize GLUT1 monoclonal antibody us-
ing immunohistochemistry staining standard protocol to 
identify the location and expression pattern of GLUT1, which 
will be graded with respect to the estimated fraction of 
malignant cells with positive and relative intense stain.
All recruited tissue specimens were paraffin-embedded 
tissue blocks and were collected along with their clinico-
pathological data from the Department of Pathology (Tab. 1). 
All paraffin blocks were cut (4 µm thickness), Hematoxy-
lin-and-Eosin (H&E) stained and reevaluated for diagnosis 
and grading confirmation by two pathologists. Later, tissue 
microarray (TMA) was built using all paraffin-embedded 
specimens of both groups (carcinomas and controls) in the 
same way as was stated by Al-Maghrabi et al. [23]. Next, 
TMA Blocks were cut into 4 µm slices, placed on coated 
slides and used later in immunohistochemistry (IHC) to 
detect GLUT1 using BenchMark autostainer (Ventana, Ari-
zona, USA), anti-GLUT1 polyclonal antibody and UltraView 
Universal diaminobenzidine (DAB) Detection Kit (Ventana 
Medical Systems, USA). A slide with trisaminomethane (tris) 
buffer instead of anti- GLUT1 polyclonal antibody were in-
cluded as a negative control in every staining procedure 
performed as well as positive tissue control of colorectal 
carcinoma as indicated by the manufacturer. 
Two pathologists analyzed the quality of GLUT1 expres-
sion and approximated the percentage of positive neo-
plastic cells. The estimations of GLUT1 positive cells were 
determined by semi-quantitative procedure in 3 micro-
scopic fields using 40 × lenses. All cases with brown color 
in less than 5% of neoplastic cells were counted negatively 
stained. Grades of 0, 1, 2, and 3 were assigned for negative, 
weak, modest and strong stain respectively. These scores are 
displayed in this report as high (2 and 3), and low (0 and 1). 
The lowest grade recorded by any pathologist was taken 
into account if a disparity occurred. 
Statistical Analysis
The data were analysed by using version 21 of Interna-
tional Business Machines-Statistical Package for the Social 
Sciences (IBM-SPSS). All results were displayed as incidences 
and percentages. The relationship between clinical factors of 
ECs and GLUT1 immunoexpression was investigated by 
Fisher and chi-square tests. Assessment of survival distribu-
tions for several GLUT1 IHC staining scores were calculated 
by using a Log Rank test. The significance level was consid-
ered at p < 0.05.
RESULTS
Clinicopathological factors of all ECs cases with the ex-
pression of GLUT1 was presented in Table 1. Transformed 
epithelium of sixty four endometrial cancer cases (90.1%) 
showed high scores GLUT1 IHC staining, and 7 (9.9%) sam-
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ples revealed negative or weak staining. High scores of 
GLUT1 IHC staining in stromal cells of ECs were found in 
the total of only 21 out of 71 cases of ECs. High scores of 
GLUT1 staining were found more frequently in cancer cases, 
it was recognized in 64 (90%) endometrial cancers compared 
to 12 (40%) control cases. Staining of the normal endome-
trial epithelium, if present, was much lower than observed 
in tumor cells from the same patient.
Biologic behavior tissue type (cancer versus non-can-
cerous) was obviously associated with GLUT1 immunohis-
tochemistry staining (p = 0.000). Significant association 
between strong GLUT1 staining of malignant epithelial cells 
and stage of tumor (p = 0.000) was observed, advanced dis-
ease stages were more prevalent with high GLUT1 staining in 
malignant epithelial cells. There is also a significant associa-
tion between high GLUT1 staining scores and cytoplasmic 
and membranous expression locations in malignant epithe-
lium (p = 0.000), 100 percent of cases (58) with cytoplasmic 
and membranous expression showed high GLUT1 staining 
scores. The remaining cases were 3 negative and ten cases 
revealed cytoplasmic staining only of which 60% were of 
strong staining. 
Most positive GLUT1 cases showed a brown color in 
greater than 50% of the transformed cells (Fig. 1 A, B, C and D). 
Substantial variability was identified in GLUT1 staining, for 
instance, some neoplasms exhibited positive stain in se-
lected glands or cells and others showed identical stain in all 
glandular or cellular parts. No significant associations were 
analysed between GLUT1 immunostaining and neoplasm 
diagnosis, grade, recurrence and alive/deceased status. 
The log rank test was used to compare survival dis-
tributions among cases of low and high GLUT1 staining 
scores. Table 2 defines the average survival times of tu-
mor patients with different clinical risk factors varied for 
Table 1. Distribution of various clinicopathological variables with Glucose transporter 1 (GLUT1) immunostaining in transformed endometrial cells
Gut 1 in Epithelial cells
p-valueLow High
n [%] n [%]
Group Control 18 60.0 12 40.0 0.000
Endometrial Cancer 7 9.9 64 90.1
GLUT1 staining location Negative 3 100 0 0.0 0.0001
Cytoplasmic 4 40.0 6 60.0
Cytoplasmic and membranous 0 0.0 58 100.0
Diagnosis Clear cell carcinoma 0 0.0 1 100.0 0.695
Endometrioid adenocarcinoma 7 11.9 52 88.1
MMMT 0 0.0 2 100.0
Serous carcinoma 0 0.0 9 100.0
Grade I 5 12.5 35 87.5 0.999
II 2 8.7 21 91.3
III 0 0.0 6 100.0
Ungraded 0 0.0 2 100.0
Stage I 6 15.4 33 84.6 0.000
II 0 0.0 5 100.0
III 0 0.0 9 100.0
IV 0 0.0 3 100.0
Unstaged 1 6.7 14 93.3
Differentiation M 2 10.0 18 90.0 0.884
NA 0 0.0 2 100.0
P 0 0.0 8 100.0
W 5 12.2 36 87.8
Recurrence No 6 10.7 50 89.3 0.999
Yes 1 6.7 14 93.3
Alive No 0 0.0 17 100.0 0.185
Yes 7 13.0 47 87.0
GLUT1 — Glucose transporter 1
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GLUT1 staining. Considerable varied survival models were 
observed with neoplasm diagnosis, grade, stage, differen-
tiation and recurrence (p-values 0.000, 0.000, 0.000, 0.002, 
and 0.000 respectively). Survival estimates are considerably 
healthier in positive GLUT1 staining cases of endometrial 
carcinoma, which have endometrioid adenocarcinoma type, 
low grade, low stage, well differentiation or no recurrence. 
On the other hand, positive neoplasms with high grade, 
high stage, poor differentiation or recurrence displayed 
poorer survival estimations. Kaplan Meier survival curves 
Figure 1. Glucose transporter 1 (GLUT1) immunostaining pattern in endometrial cancer; A — strong staining in endometrial tissue; B — moderate 
staining in endometrial cancer; C — weak staining in endometrial cancer; D — negative staining in endometrial cancer
Table 2. Comparison of survival distribution patterns by various clinicopathological variables in positive Glucose transporter 1 (GLUT1) 
immunostained endometrial cancers
n No. of Events Mean S.E p-valuea
Grade I 40 4 105.016 7.000 0.000
II 21 6 95.970 13.932
III 6 5 20.154 7.048
Ungraded 2 1 11.187 5.401
Stage I 38 2 108.154 6.788 0.000
II 5 1 59.644 12.330
III 8 7 26.801 14.952
IV 3 3 22.198 14.932
Unstaged 15 3 97.449 10.617
Differentiation W 41 4 106.066 6.523 0.002
M 18 6 87.111 16.245
P 8 5 45.745 15.734
NA 2 1 11.187 5.401
Recurrence No 55 7 102.797 6.065 0.000
Yes 14 9 45.930 14.736
Diagnosis Endometrioid adenocarcinoma 59 8 114.965 7.348 0.000
MMMT 2 1 11.187 5.401
Serous carcinoma 8 7 25.741 6.823
a — Log-Rank test adjusted for GLUT1 immunostaining
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exhibited significant improved survival experience in cases 
of endometrioid adenocarcinoma type, low grade, low stage 
well differentiation or no recurrence (Fig. 2).
 DISCUSSION
Glucose transporters have become one of the core 
subjects in cancer biology since it has been found that 
neoplastic cells show higher glucose metabolism in com-
parison with normal tissue. The resultant big growth in 
glucose necessity indicates a demand for a consistent rise 
in the transportation of glucose through the cell membrane. 
The greater part of tumors show increased expression of 
GLUT1 that has been existed in relevant normal counter-
part tissues in non-cancerous states. Furthermore, because 
of the need for power to serve unrestrained proliferation, 
neoplastic cell frequently expresses GLUT1 that would not 
be expressed in the cells in ordinary circumstances [24–25]. 
The level and membranous location of GLUT1 expression 
could be an appropriate biomarker of glucose metabolism 
that might be assessed easily and economically as part of 
the histologic assessment practice of neoplasms [19]. Since 
increased expression of GLUT1 is already known in many 
neoplasms, its relationship with prognostic parameters has 
been studied [8–10]. The earliest and the most striking study 
on this subject to date is the one that was conducted on co-
lon cancer. In addition to indicating GLUT1 as a good marker 
to determine aggressive biological behavior of colorectal 
carcinomas, it also showed a direct correlation between 
lymph node metastases and GLUT1 expression [26]. 
In endometrial neoplasms, nevertheless, many studies 
[11–22] tried to find a comparable association and verify that 
the IHC GLUT1 phenotype could be utilized as a diagnostic and 
prognostic tissue marker, but the findings were inconsistent 
(Tab. 3). In agreement with the majority of literature data, our 
Figure 2. Kaplan Meier Survival Curves by various clinicopathological variables with Glucose transporter 1 (GLUT1) immunostaining in endometrial cancer
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results were capable statically to show increased cytoplasmic 
and/or membranous expression of GLUT1 in ECs compared 
to normal endometrium [11–22]. Decreased GLUT1 expres-
sion in normal endometrium as well as its weak expression 
in non-cancerous lesions and overexpression in endometrial 
cancer suggests that this molecule might be involved in en-
dometrial carcinogenesis as the findings of this study and oth-
ers [12, 14] showed significant association with tumor stage. 
On the other hand, some studies including the present one 
could not demonstrate any significant relationship between 
GLUT1 expression and other prognostic parameters of ECs 
[11, 15–20, 22]. While, few studies found that the association 
between GLUT1 phenotype and clinical data, i.e. increasing 
grade and stage, is statistically significant [12, 14]. Goldman et 
al. (2006) [21] and later Canpolat et al. (2016) [13] reported that 
among clinical characteristics, only grade was found to be sig-
nificantly correlated to GLUT1 expression. According to Xiong 
et al. [16], the expression of GLUT1 can be used to distinguish 
between benign endometrial lesions and endometrial cancer 
but has no prognostic value in women with this malignancy. 
This is opposite to the present investigation which showed 
significant differences in the expression of GLUT1 associated 
with clinical stage or prognosis in endometrial cancer patients.
The present investigation showed that the impact of 
GLUT1 phenotype on the survival estimates of endometrial 
cancer was modified significantly by some clinical factors, 
including the type of tumor, grade, stage and recurrence. 
This finding is in line with the recent analyses of numerous 
studies which have reported paradoxical evidence of the 
relationship between GLUT1 expression and prognosis in 
solid human tumors [8, 27].
The differences between the previous studies and the 
current one could be clarified by method sensitivity, people’s 
difference, and variations in the size of samples. The present 
report and previous similar ones which evaluated the diag-
nostic and prognostic power of GLUT1 immunoreactivity 
in endometrial malignancy had weak points such as the 
relatively small sample size involved in these studies and 
the semi-quantitative interpretation of immunostaining. 
However, greater inclusive studies are undoubtedly of great 
value for estimating the diagnostic and prognostic values 
of GLUT1 immunoreactivity in endometrial malignancy. 
CONCLUSIONS 
Our results showed increased expression of GLUT1 in 
endometrial tumors. IHC staining of GLUT1 can be a sup-
portive mean in predicting prognosis and survival estimates 
of endometrial tumors with specific clinical factors.
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Table 3. Correlation between high level of Glucose transporter 1 (GLUT1) immunoreactivity and clinicopathological parameters of endometrial 













The current study 90%p = 0.0001 40%
CM
p = 0.0001 NS 0.000 NS NS p = 0.005
Nemejcova et al. 2017 [11] 90% 33% M
Anagnostou et al. 2017 [20] 63% M NS
Al-Sharaky et al. 2016 [12] 98.5%p = 0.008 88.9% CM p = 0.003 p = 0.004
Canpolat et al. 2016 [13] 95% 31.9% M p = 0.007 NS NS
Ma et al. 2015 [14] 70%p < 0.05 14% N p < 0.05 p < 0.05
Sadlecki et al. 2014 [15] 100% CM NS NS NS NS
Xiong et al. 2010 [16] 71% 0% M
Wahl et al. 2010 [22] 53% 0% M
Ashton-Sager et al. 2006 [17] 90% 17% M
Goldman et al. 2006 [21] present present C p < 0.002
Sebastiani et al. 2004 [18] 43% M NS
Wang et al. 2000 [19] 100% 0% M
GLUT1 — Glucose transporter 1; C — cytoplasmic; M — membranous; CM — cytoplasmic and membranous; N — nuclear; NS — not significant
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